CD19 and acute lymphoblastic leukemia: Given the widespread use of CD19 CAR T therapy in both clinical trials and the clinic and the association of lack of CAR T persistence with relapse in ALL [8,9], real-time assessment of CAR T cell persistence is imperative in routine diagnostic laboratories.